Ibritumomab Tiuxetan Radioimmunotherapy for Primary Gastrointestinal Follicular Lymphoma.
Sanjal H DesaiMuhamad Alhaj MoustafaGregory WisemanThomas WitzigPublished in: The oncologist (2021)
Primary gastrointestinal follicular lymphoma (PGIFL) is characterized by localized involvement of the gastrointestinal (GI) tract. PGIFL usually runs an indolent course. External beam radiation therapy is curative in a substantial proportion of localized follicular lymphomas, but GI toxicities may discourage its use in PGIFL. Ibritumomab tiuxetan radioimmunotherapy (RIT) is a radioimmunoconjugate of anti-CD20 monoclonal antibody linked to chelator tiuxetan and radioisotope. RIT delivers confined high-intensity radiation with short path length specifically targeting lymphoma cells and sparing normal tissue. In this case series report, we included six cases of PGIFL treated with RIT. All patients had low-risk, localized, and nonbulky disease. All patients responded completely and were relapse-free for the duration of follow-up. Hematologic toxicities were seen, but none were serious. RIT is a potentially curative treatment option in PGIFL with a tolerable toxicity profile.
Keyphrases
- end stage renal disease
- high intensity
- radiation therapy
- prognostic factors
- newly diagnosed
- ejection fraction
- chronic kidney disease
- monoclonal antibody
- peritoneal dialysis
- induced apoptosis
- patient reported outcomes
- cell death
- cell proliferation
- signaling pathway
- pi k akt
- combination therapy
- free survival
- replacement therapy